"bluebird has the largest and deepest ex-vivo gene therapy data set in the field".
This class action is dark times - but it's misplaced, and it will fail, with one of the defensible factors being the removal of "multiple undisclosed" from the pipeline page. That's not a pocket-ace for the sharks, if ya follow. I feel for those that lost, and I am down also - but this is solely on the FDA, and nobody's gonna sue them, sadly. All these sharks...trying to hold Bluebird accountable for ...forward-planning and a lack of caution by analysts?? Geez...the type-set was clear.
Pretty good buy action today, IMO. I've got a little left in the tank, and I see no reason to assume 30%+ share equity increase, but baking-in the value of 2500 therapy instances on 200m is a lot to wrap. Back to top, future...................unknown.
Bullish
Market Data 
Markets 
AI
